Rollover GlaxoSmithKline TESARO-sponsored niraparib study
People with Ovarian Cancer are asked to participate in a research study being conducted by Monter Cancer Center.
You may be eligible to participate in this study if you:
• Understand the study procedures and agrees to participate in the study by providing written informed consent.
• Are currently receiving treatment with niraparib
• Are currently benefiting from treatment with niraparib as assessed by the Investigator
You may NOT participate in this study if you:
• Have been permanently discontinued from niraparib treatment in the parent study for any reason.
• Currently have unresolved toxicities for which niraparib dosing has been interrupted in the parent study
• Are pregnant or breastfeeding
Contact Information
Mary Agnes Templeton, Study Coordinator
450 Lakeville Road
Lake Success, New York 11042
Phone: (516) 734-8979
Fax: (516) 734-8909
Email: MTEMPLETON@NORTHWELL.EDU
Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Women with Ovarian Cancer are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.
You may be eligible to participate in this study if you:
- Are a female at least 18 years of age
- Have a confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer
- Have platinum-resistant disease
- Have completed any major surgery at least 4 weeks prior to first dose of
MIRV and have recovered or stabilized from the side effects of prior surgery
- Have adequate hematologic, liver and kidney functions
You may NOT participate in this study if you:
- Have primary platinum-refractory disease
- Have folate deficiency (take folate supplements)
- Have active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring
- Have a serious concurrent illness or clinically relevant active infection
- Have a clinically significant cardiac disease
- Have a history of hemorrhagic or ischemic stroke or a history of cirrhotic liver disease
- Are pregnant or breastfeeding
Contact Information
Martina Kracikova, Study Coordinator
One Gustave L. Levy Place, Box 1170 New York, NY 10029
Phone: (212)-824-7859
Fax: (212) 824 2347
Email: martina.kracikova@mssm.edu
Ovarian Cancer (OVATION 2)
People with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer are asked to participate in a research study being conducted by Northwell Health.
You may be eligible to participate in this study if you:
- Are a female at least 18 years of age or older
- Have histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
You may not participate in this study if you:
- Have received prior chemotherapy for any abdominal or pelvic tumor
- Are receiving treatment for active autoimmune disease such as systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis
- Have known hepatitis
- Are pregnant or breastfeeding
Contact Information
Sarah Davis, Study Coordinator
Monter Cancer Center
450 Lakeville Road
Lake Success, New York 11042
Phone: (516) 734-7632
Email: sdavis22@northwell.edu
19-11-175 / TX226752
Platinum-Resistant Ovarian Cancer
A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208)
Women with platinum resistant ovarian cancer are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.
You may be eligible to participate in this study if you:
- Are a female at least 18 years of age or older
- Have histologic documentation of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
You may not participate in this study if you:
- Have primary platinum-refractory disease, defined as disease progression within 2 months of completion of first line platinum-based therapy
- Have had gastrointestinal obstruction within the past 6 months or who currently require parenteral nutrition
- Have known past or current coagulation defects leading to an increased risk of bleeding
- Have clinically significant cardiac disease
- Have active ocular surface disease
- Have ongoing, acute, or chronic inflammatory skin disease
- Have uncontrolled tumor-related pain
- Have Inflammatory lung disease requiring chronic medical therapy
- Have Grade 3 or higher pulmonary disease unrelated to underlying malignancy
- Have Grade >1 peripheral neuropathy
- Have inflammatory bowel disease including Crohn’s disease and ulcerative colitis
- Are pregnant, breastfeeding or plan to become pregnant
Contact Information
Martina Kracikova, PhD, Study Coordinator
One Gustave L. Levy Place, Box 1170
New York, New York 10029
Phone: 212 824 7859
Email: martina.kracikova@mssm.edu